Toujeo SoloStar: Long-Acting Insulin Pen Guide

Toujeo SoloStar is a prefilled insulin pen containing concentrated insulin glargine (U-300) used once daily as basal insulin in adults and children with type 1 or type 2 diabetes. The concentrated formulation provides a flatter, longer-lasting glucose-lowering effect than Lantus (U-100), with duration reaching up to 36 hours. It is injected once daily at the same time each day.

What Makes Toujeo Different

Toujeo contains the same insulin glargine molecule as Lantus and Semglee, but at three times the concentration — 300 units per milliliter instead of 100. A higher concentration means each dose requires one-third the volume of fluid. The smaller subcutaneous depot has less surface area, so insulin is released more slowly and steadily over the following day.

The practical benefits are a flatter 24-hour pharmacokinetic profile, a longer duration (up to 36 hours in some patients), and modestly lower risk of nocturnal hypoglycemia compared with U-100 glargine. For a broader view of medication options in diabetes, see our treatment overview.

Who Uses Toujeo

Toujeo is FDA-approved for:

• Adults with type 1 or type 2 diabetes requiring basal insulin
• Children age 6 and older
• Patients switching from Lantus or NPH for less nocturnal hypoglycemia
• High-dose users who benefit from the smaller injection volume
• Those needing a once-daily basal option with slightly more timing flexibility

Onset, Peak, and Duration

Dosing and Titration

Typical starting doses:

• Insulin-naive type 2 diabetes: 0.2 units per kilogram once daily
• Type 1 diabetes: roughly 50% of total daily insulin delivered as basal
• Switching from once-daily Lantus or Semglee: unit-for-unit at first, expect to increase by 10 to 15 percent over a few weeks
• Switching from twice-daily NPH: start at 80% of the total NPH daily dose, given once daily

Titrate every 3 to 4 days — typically in 2- to 4-unit steps — based on fasting glucose, aiming for 80 to 130 mg/dL. Because Toujeo takes up to 5 days to reach steady state, wait at least 3 to 5 days before judging the effect of a dose change.

How to Use the SoloStar Pen

1. Inspect the pen — Toujeo is clear and colorless; discard if cloudy or particulate
2. Attach a new pen needle (4 mm or 5 mm for most adults and children)
3. Prime with 3 units, holding the pen with the needle pointing up
4. Dial the prescribed dose (1-unit increments)
5. Inject into the subcutaneous fat of the abdomen, thigh, or upper arm
6. Press the dose button fully and count to 5 before withdrawing the needle
7. Remove and discard the needle in a sharps container
8. Record the time and dose; rotate sites from day to day

Two SoloStar pen sizes exist: standard SoloStar holds 450 units (up to 80 units per injection) and Max SoloStar holds 900 units (up to 160 units per injection) for patients on high daily doses.

Common Side Effects

• Hypoglycemia (most common, especially during titration)
• Injection-site reactions — redness, itching, swelling
• Weight gain of a few pounds
• Lipohypertrophy with repeated same-site injection
• Rare allergic reactions

Serious Warnings

Hypoglycemia

Severe hypoglycemia can cause seizure, loss of consciousness, or rarely death. Toujeo produces less nocturnal hypoglycemia than U-100 glargine in clinical trials, but the risk is never zero. Family members should know how to use glucagon. Talk to your care team about how your A1C goal affects dosing decisions — tighter targets carry more risk.

Never Share Pens

Sharing a pen, even with a new needle, can transmit blood-borne infections. Each patient must use only their own SoloStar pen.

Hypokalemia

Insulin shifts potassium into cells. Patients on diuretics, with kidney disease, or with baseline low potassium need closer monitoring.

Fluid Retention with Thiazolidinediones

Combining Toujeo with pioglitazone or rosiglitazone raises the risk of fluid overload and heart failure.

Hypersensitivity

Severe allergic reactions are rare but possible. Stop Toujeo and seek emergency care for widespread rash, facial swelling, difficulty breathing, or rapid heartbeat after injection.

Drug Interactions

Beta-blockers may mask hypoglycemia symptoms. Corticosteroids, atypical antipsychotics, and thiazide diuretics can raise insulin needs. Alcohol can prolong hypoglycemia. Keep an updated medication list with your pharmacist.

Storage and Handling

• Unopened SoloStar pens: refrigerate at 36 to 46 degrees Fahrenheit until expiration date
• In-use pens: room temperature below 86 degrees for up to 56 days (longer than most analogs)
• Never freeze; protect from direct sunlight and heat
• Always remove the pen needle after each dose to prevent leaks and contamination

Cost and Insurance Coverage

Toujeo is usually covered by commercial insurance and Medicare Part D, often at a similar tier as other long-acting analogs. Access programs include:

• Sanofi Insulins Valyou Savings Program — caps out-of-pocket cost at $35 per month for eligible patients
• Medicare Part D $35 insulin cap under the Inflation Reduction Act
• Sanofi patient assistance program for qualifying uninsured patients
• State insulin affordability laws in many states

Toujeo vs. Tresiba

Both offer longer and flatter basal coverage than U-100 glargine. Head-to-head trials (BRIGHT) showed similar A1C reductions with Toujeo and Tresiba, and similar overall hypoglycemia rates. Tresiba’s 42-hour duration offers the most timing flexibility. Toujeo is familiar because it uses the same glargine molecule as Lantus and Semglee. Coverage and out-of-pocket cost often drive the choice.

Monitoring on Toujeo

• Fasting glucose every morning during titration, then daily or as your plan directs
• A1C every 3 months until at goal, then every 6 months
• Injection sites monitored for lumps or induration
• Annual eye, foot, and kidney screening
• Review of hypoglycemia episodes at every visit

When to Contact Your Care Team

• Severe hypoglycemia or nighttime lows you cannot explain
• Fasting glucose persistently above 180 mg/dL after 2 weeks of titration
• Rapid weight gain, swelling, or shortness of breath
• Planning pregnancy, surgery, or sick days
• New medications, especially corticosteroids
• Suspected allergic reaction

The Bottom Line

Toujeo SoloStar is a concentrated long-acting basal insulin that offers flatter 24-hour coverage and slightly less nocturnal hypoglycemia than Lantus, delivered through a convenient prefilled pen. Patients switching from U-100 glargine often need a small dose increase to match fasting glucose targets. Alongside a rapid mealtime insulin or oral agents, Toujeo can help adults with type 2 diabetes and type 1 patients reach their A1C goals. Discuss with your clinician whether Toujeo’s profile fits your schedule, coverage, and treatment plan.